Tactile Systems Technology, Inc.

NasdaqGM TCMD

Tactile Systems Technology, Inc. Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending September 30, 2024: 8.80%

Tactile Systems Technology, Inc. Return on Capital Employed (ROCE) is 8.80% for the Trailing 12 Months (TTM) ending September 30, 2024, a 65.59% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

Tactile Systems Technology, Inc. Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending September 30, 2023 was 5.31%, a 159.40% change year over year.
Tactile Systems Technology, Inc. Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending September 30, 2022 was -8.94%, a -900.58% change year over year.
Tactile Systems Technology, Inc. Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending September 30, 2021 was 1.12%, a 131.67% change year over year.
Tactile Systems Technology, Inc. Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending September 30, 2020 was -3.53%, a -153.59% change year over year.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

NasdaqGM: TCMD

Tactile Systems Technology, Inc.

CEO	Ms. Sheri Louise Dodd
IPO Date	July 28, 2016
Location	United States
Headquarters	3701 Wayzata Boulevard
Employees	992
Sector	Health Care
Industries Medical Instruments Pharmaceuticals Telehealth

Description

Tactile Systems Technology, Inc., a medical technology company, engages in the development and provision of medical devices for chronic diseases in the United States. The company offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema; Entre system, a portable pneumatic compression device that is used for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers; and AffloVest, a portable high frequency chest wall oscillation test for the treatment of retained pulmonary secretions such as bronchiectasis, cystic fibrosis, and various neuromuscular disorders. The company was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.

Key trends

Past 5 years